Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Hepatology (Baltimore, Md.) 2024 Oct 18
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
Related Questions
How do you choose between resmetirom and semaglutide in the treatment of MASH?
21600
×
To continue please login or register
Register
or
Sign in
